S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
NASDAQ:CDXC

ChromaDex (CDXC) Stock Price, News & Analysis

$1.61
-0.06 (-3.59%)
(As of 03/1/2024 ET)
Today's Range
$1.61
$1.69
50-Day Range
$1.36
$1.73
52-Week Range
$1.25
$1.99
Volume
37,452 shs
Average Volume
76,013 shs
Market Capitalization
$120.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.80

ChromaDex MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
260.2% Upside
$5.80 Price Target
Short Interest
Bearish
2.99% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.83
Upright™ Environmental Score
News Sentiment
0.70mentions of ChromaDex in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From $24.68 to ($0.02) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.49 out of 5 stars

Medical Sector

311th out of 950 stocks

Medicinals & Botanicals Industry

1st out of 11 stocks


CDXC stock logo

About ChromaDex Stock (NASDAQ:CDXC)

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.

CDXC Stock Price History

CDXC Stock News Headlines

ChromaDex (CDXC) to Release Earnings on Wednesday
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
ChromaDex (NASDAQ:CDXC) Now Covered by StockNews.com
Top 3 Accelerating Chemical Stocks to Consider
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
ChromaDex: Growth At A Reasonable Price
ChromaDex Flat on Assistance to Military
ChromaDex: Q3 Earnings Insights
Earnings Outlook For ChromaDex
See More Headlines
Receive CDXC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ChromaDex and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/08/2023
Today
3/02/2024
Next Earnings (Confirmed)
3/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medicinals & botanicals
Sub-Industry
N/A
Current Symbol
NASDAQ:CDXC
Employees
113
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.80
High Stock Price Target
$6.60
Low Stock Price Target
$5.00
Potential Upside/Downside
+260.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-16,540,000.00
Pretax Margin
-7.76%

Debt

Sales & Book Value

Annual Sales
$72.05 million
Book Value
$0.39 per share

Miscellaneous

Free Float
67,183,000
Market Cap
$120.94 million
Optionable
Optionable
Beta
1.87
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Frank Louis Jaksch Jr. (Age 56)
    Co-Founder & Chairman
    Comp: $292.27k
  • Mr. Robert N. FriedMr. Robert N. Fried (Age 64)
    CEO & Director
    Comp: $735.54k
  • Ms. Brianna Gerber (Age 43)
    Chief Financial Officer
    Comp: $509.82k
  • Dr. Andrew Shao Ph.D.
    Senior Vice President of Global Regulatory & Scientific Affairs
  • Heather Van Blarcom
    Senior VP of Legal & Corporate Secretary
  • Alex Worsham
    Vice President of Global Marketing & Communications
  • Mr. David Kroes
    Senior Vice President of People Matters
  • Ms. Chu Yan
    Managing Director of Asia Pacific
  • Mr. Jason Campbell
    Senior Vice President of Business Development
  • Kendall Knysch
    Head of Media Relations & Partnerships














CDXC Stock Analysis - Frequently Asked Questions

Should I buy or sell ChromaDex stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ChromaDex in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CDXC shares.
View CDXC analyst ratings
or view top-rated stocks.

What is ChromaDex's stock price target for 2024?

1 Wall Street analysts have issued 12-month price objectives for ChromaDex's stock. Their CDXC share price targets range from $5.00 to $6.60. On average, they predict the company's stock price to reach $5.80 in the next twelve months. This suggests a possible upside of 260.2% from the stock's current price.
View analysts price targets for CDXC
or view top-rated stocks among Wall Street analysts.

How have CDXC shares performed in 2024?

ChromaDex's stock was trading at $1.43 at the beginning of the year. Since then, CDXC shares have increased by 12.6% and is now trading at $1.61.
View the best growth stocks for 2024 here
.

When is ChromaDex's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024.
View our CDXC earnings forecast
.

How can I listen to ChromaDex's earnings call?

ChromaDex will be holding an earnings conference call on Wednesday, March 6th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 800-770-2030 with passcode "8584242".

How were ChromaDex's earnings last quarter?

ChromaDex Co. (NASDAQ:CDXC) posted its quarterly earnings results on Wednesday, March, 8th. The company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.01. The business earned $21 million during the quarter, compared to analyst estimates of $21.08 million. ChromaDex had a negative trailing twelve-month return on equity of 23.28% and a negative net margin of 7.76%. During the same period in the prior year, the business earned ($0.08) EPS.

What is Robert Fried's approval rating as ChromaDex's CEO?

13 employees have rated ChromaDex Chief Executive Officer Robert Fried on Glassdoor.com. Robert Fried has an approval rating of 38% among the company's employees. This puts Robert Fried in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 46.0% of employees surveyed would recommend working at ChromaDex to a friend.

What other stocks do shareholders of ChromaDex own?
Who are ChromaDex's major shareholders?

ChromaDex's stock is owned by many different institutional and retail investors. Top institutional shareholders include Tieton Capital Management LLC (3.88%), Gabelli Funds LLC (0.27%), Royal Bank of Canada (0.16%), Silverberg Bernstein Capital Management LLC (0.11%), International Assets Investment Management LLC (0.04%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Brianna Gerber, Frank L Jaksch Jr, Hoi Shuen Solina Holly Chau, Robert N Fried, Stephen A Block and Steven D Rubin.
View institutional ownership trends
.

How do I buy shares of ChromaDex?

Shares of CDXC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CDXC) was last updated on 3/2/2024 by MarketBeat.com Staff